Trouble viewing this email?  View in web browser ›

The Wall Street Journal ProThe Wall Street Journal Pro
Venture CapitalVenture Capital

SVB Crisis Puts Pressure on Healthcare Venture Financing Market

By Brian Gormley, WSJ Pro

 

Good day. Silicon Valley Bank’s crisis puts pressure on a venture financing market that had already compressed for healthcare startups.

SVB emerged as a go-to financial partner for startups and venture capitalists because of its willingness to tailor loans and lines of credit to their needs, entrepreneurs and investors said. 

Now startups could face a tougher road when seeking venture debt, said Heath Naquin, who helps digital-health startups navigate the venture landscape as vice president of government and capital engagement for University City Science Center, a Philadelphia-based nonprofit.

"If those products and services they offered go away, it will slow down both the pace of the growth of those companies as well as the pace of investment," he added.

Venture investment into healthcare-IT and digital-health startups has fallen recently as these companies have faced headwinds when selling to hospitals, health systems and employers, according to Rebecca Springer, senior analyst and healthcare lead for market tracker PitchBook Data Inc. That is likely to make general partners of venture firms more cautious.

“SVB’s collapse will make GPs even more risk-averse, leading to limited funding options for startups that do not have a clear path to profitability in this challenging climate,” Dr. Springer said. “We expect deal figures to remain low and to see further valuation declines and consolidation in many corners of the healthtech ecosystem.”

During the financing boom of 2020 and 2021, biotechnology startups raced to go public. Now initial public offerings have grown scarce, and SVB’s troubles threaten to make going public even more difficult.

“This event extended out the concept that it may be a little while longer before that IPO market comes back robustly,” said Chris Garabedian, founder and CEO of life sciences accelerator Xontogeny. 

And now on to the news...

 
Advertisement
LEAVE THIS BOX EMPTY
 

Top News

About 12% of Silicon Valley Bank’s client deposits of $173 billion came from the life sciences and healthcare sector. PHOTO: BRIAN L. FRANK FOR THE WALL STREET JOURNAL

Biotechnology. The sudden collapse of Silicon Valley Bank was supposed to have been fixed by Sunday afternoon when federal regulators said they would make depositors whole starting Monday. But early this week, some companies were still left hurrying to make sure they could make this week’s payroll, The Wall Street Journal reports.

  • In biotech—a sector where many startups relied on SVB—some were still finalizing the opening of new checking accounts to pay their employees from; and many of those who tried to move their funds out of their SVB accounts were unable to do so because the bank’s website kept crashing.
     
  • Many biotechs used their SVB accounts to pay their bills and to draw their payroll funds. Making payroll was foremost among many executives’ minds—payments to vendors could be delayed, but state and federal laws require companies to make timely wage payments to employees.
     
  • About 12% of SVB’s client deposits of $173 billion came from the life sciences and healthcare sector, SVB said in its fourth-quarter earnings report.  

With SVB Stabilized, Some Restore Banking Relationship

Venture investors and startups are starting to return deposits to the revamped Silicon Valley Bank, whether in hopes of helping stabilize the institution so it survives, or out of necessity, WSJ Pro’s Yuliya Chernova and Marc Vartabedian report. The reversal comes as the chief executive of Silicon Valley Bridge Bank—created by federal regulators to manage Silicon Valley Bank deposits and assets—has gone on a charm offensive to persuade clients to stay with the bank.

$43 Billion

The amount drugmaker Pfizer Inc. agreed to pay to acquire biotechnology company Seagen Inc.

First Drugs Facing Medicare Price Penalty Are Named

U.S. health officials released the first list of drugs paid for by the government’s Medicare insurance program whose prices went up more than the rate of inflation and will face a penalty under a new federal law, WSJ reports. The Centers for Medicare and Medicaid Services on Wednesday named 27 drugs that had the large price increases, including  rheumatoid-arthritis treatment Humira from AbbVie Inc. and Yescarta lymphoma therapy from Gilead Sciences Inc., and will face the price-increase penalty in the form of a rebate.

 
Advertisement
LEAVE THIS BOX EMPTY
 
Share this email with a friend.
Forward ›
Forwarded this email by a friend?
Sign Up Here ›
 

Industry News

People

Bryn Pharma LLC, an anaphylaxis treatment startup, named Sandy Loreaux to the post of chief executive, replacing David Dworaczyk. Ms. Loreaux most recently led Covis Pharma’s U.S. operations. 

 
Advertisement
LEAVE THIS BOX EMPTY
 

New Money

Switch Therapeutics, a South San Francisco, Calif.-based startup using RNA science to treat diseases, secured $52 million in Series A financing co-led by Insight Partners and UCB Ventures.

Fount, a Los Angeles-based startup offering customized health and performance optimization programs, nabbed $12 million in Series A funding led by Amity Ventures.

 

More Health News

As a result of the cuts to list prices of insulin, uninsured people and those with high-deductible health plans could see reduced costs. PHOTO: ALEX FLYNN/BLOOMBERG NEWS

  • Novo Nordisk to slash insulin prices by up to 75%
     
  • Biden hits GOP on drug prices in campaign battleground state of Nevada
     
  • New health research agency, ARPA-H, starts search for two hub locations
     
  • Pfizer overpays for Seagen, but who’s counting
 
Advertisement
LEAVE THIS BOX EMPTY
 

Around the Web

  • In Minnesota, researchers explore how to audit health AI models on a patient level (STAT)
     
  •  The future of Covid-19 research. (New England Journal of Medicine)
     
  • Bristol-Myers meets some diversity goals early, while missing others (Endpoints News)
     
  •  Opioid settlement hinders access to a wide array of drugs (New York Times)
 

The WSJ Pro VC Team

This newsletter was compiled by Matthew Strozier, Zachary Cole and Brian Gormley.

WSJ Pro Venture Capital is a premium service of The Wall Street Journal. We cover venture capital and the global startup ecosystem. Share your tips, comments and questions: vcnews@wsj.com

The Team: Matthew Strozier, Yuliya Chernova, Brian Gormley, Angus Loten, and Marc Vartabedian.

Follow us on Twitter: @wsjvc

 
Desktop, tablet and mobile. Desktop, tablet and mobile.
Access WSJ‌.com and our mobile apps. Subscribe
Apple app store icon. Google app store icon.
Unsubscribe   |    Newsletters & Alerts   |    Contact Us   |    Privacy Notice   |    Cookie Notice
Dow Jones & Company, Inc. 4300 U.S. Ro‌ute 1 No‌rth Monm‌outh Junc‌tion, N‌J 088‌52
You are currently subscribed as [email address suppressed]. For further assistance, please contact Customer Service at wsjpro‌support@dowjones.com or 1-87‌7-891-2182.
Copyright 2023 Dow Jones & Company, Inc.   |   All Rights Reserved.
Unsubscribe